Thank you for your business, support and partnership in 2020! Medicilon appreciates working with you and hope that the coming year will bring you happiness
Jan 29th, 2021 – CDE announced that the innovative drug, 3D011-08 from 3D Medicines, was approved of conducting clinical trials. It indicates that 3D Medicines
Jan.27, 2021 – Xuanzhu Biotech announced that their XZP-5610, a new treatment for NASH (non-alcoholic steatohepatitis), was approved of clinical trials by China NMPA. XZP-5610
Recently, Shanghai Medicilon was awarded the title of “Excellent Expert Workstation” by the Shanghai Academician and Expert Workstation Guidance Office and the title of “2020
